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Abstract
The Brugada syndrome (BrS) is an inherited arrhythmia characterized by
ST-segment elevation in V1–V3 leads and negative T wave on standard ECG.
BrS patients are at risk of sudden cardiac death (SCD) due to ventricular
tachyarrhythmia. At least 17 genes have been proposed to be linked to BrS,
although recent findings suggested a polygenic background. Mutations in
SCN5A, the gene coding for the cardiac sodium channel Nav1.5, have been
found in 15–30% of index cases. Here, we present the results of clinical,
genetic, and expression studies of a large Iranian family with BrS carrying a
novel genetic variant (p.P1506S) in SCN5A. By performing whole-cell patch-
clamp experiments using HEK293 cells expressing wild-type (WT) or
p.P1506S Nav1.5 channels, hyperpolarizing shift of the availability curve, depo-
larizing shift of the activation curve, and hastening of the fast inactivation
process were observed. These mutant-induced alterations lead to a loss of
function of Nav1.5 and thus suggest that the p.P1506S variant is pathogenic.
In addition, cascade familial screening found a family member with BrS who
did not carry the p.P1506S mutation. Additional next generation sequencing
analyses revealed the p.R25W mutation in KCNH2 gene in SCN5A-negative
BrS patients. These findings illustrate the complex genetic background of BrS
found in this family and the possible pathogenic role of a new SCN5A genetic
variant.
Introduction
The Brugada syndrome (BrS) is an inherited arrhythmia
characterized by ST-segment elevation in the right precor-
dial leads on the ECG and is associated with an increased
risk of sudden cardiac death (SCD) from polymorphic
ventricular tachycardia and ventricular fibrillation (Brug-
ada and Brugada 1992; Wilde et al. 2002; Antzelevitch
et al. 2003). The prevalence of BrS is estimated between
1:2,000 and 1:100,000 in different countries (Antzelevitch
et al. 2005; Probst et al. 2010; Risgaard et al. 2013). It is
commonly accepted that BrS is inherited by an autosomal
dominant mode with a strong male predominance (Antz-
elevitch et al. 2003).
Recently, seventeen susceptibility genes were identified
for BrS. However, mutations in these genes account for
only 35–40% of familial BrS (Nielsen et al. 2013), and
15–30% of the identified mutations are located in SCN5A,
the gene encoding the cardiac sodium channel Nav1.5
(Probst et al. 2009; Kapplinger et al. 2010). Indeed, more
than 370 mutations in the SCN5A gene were found in
probands with BrS. Many of these were functionally
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characterized in cell lines expressing mutant Nav1.5 chan-
nel and have shown a loss-of-function effect on sodium
current (The gene connection for the heart. http://triad.
fsm.it/cardmoc/). However, it was found that some large
BrS-affected families contained SCN5A-positive and
SCN5A-negative family members, and it put the question
about direct causative role of SCN5A gene in BrS (Probst
et al. 2009). Furthermore, recent findings suggest that
common genetic variants in other genes might have a
strong impact on the manifestation of genetic diseases
such as BrS (Bezzina et al. 2013).
In the current study, we report a large Iranian family
with BrS carrying an unusual combination of two rare
genetic variants, p.P1506S in the SCN5A gene and
p.R25W in the KCNH2 gene.
Material and Methods
The present study was performed in accordance with the
Helsinki Declaration and local ethics committee. Written
informed consent for clinical and genetic evaluation was
obtained from each member of the family. Some family
members have declined detailed clinical examinations or
genetic testing after the first consultation, and their clini-
cal and genetic data are presented when available.
Clinical evaluation
The clinical follow-up included a review of personal and
familial history complete physical examination, 12-lead
ECG, 24-hour Holter ECG monitoring, and echocardiog-
raphy. A flecainide (400 mg/oral) challenge test was per-
formed for three family members (II.3, III.1, and III.9) as
described in (Benito et al. 2009).
Genetic study
Genetic screening for mutations in SCN5A gene was per-
formed by PCR-based bidirectional capillary Sanger
sequencing. Originally designed oligonucleotide primers
encompassed all 28 exons and ~150-bp adjacent intronic
areas. The primers can be provided on request. Cascade
familial screening for genetic variants of interest was per-
formed by PCR-RFLP. The prevalence of new genetic
variants was assessed in a group of 100 healthy ethnically
matched volunteers (200 chromosomes). An additional
genetic study was performed by semiconductor sequenc-
ing platform Personal Genome Machine (PGM Ion Tor-
rent; Thermo Fisher Scientific Brand, Waltham, MA)
based on multiplex PCR primer pools designed by Amp-
liseq designer service. Mutation screening was performed
for KCNQ1, KCNE2, KCNE3, KCNE1, KCNJ2, KCNH2,
SCN5A, SCN1B, SCN3B, SCN4B, and SNTA1 genes.
Site-directed mutagenesis
Site-directed mutagenesis was performed on pCDN3.1-
hSCN5A using the Quick-Change II XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to
the manufacturer’s instructions. The resulting Nav1.5 pro-
tein is a splice variant lacking a glutamine at position
1077 (Q1077del). Thus, the P1506S substitution corre-
sponds to the P1505S in the used SCN5A sequence.
Cellular electrophysiology
Human Embryonic Kidney 293 cells (HEK293) were cul-
tured at 37°C in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% FBS (fetal bovine
serum), 4 mmol/L glutamine, and a cocktail of strepto-
mycin–penicillin antibiotics in a humidified atmosphere
of 5% CO2 and 95% air. All cell medium components
except glutamine (Sigma–Aldrich) were purchased from
Gibco. The HEK293 cells were transfected with DNA
complexed to JetPEI (Polyplus-transfection) according to
the manufacturer’s instructions. DNA concentrations were
1 lg of pCDN3.1- Nav1.5 wild type (WT), p.P1505S and
1 lg of pIRES-hb1-CD8. Six to eight hours after transfec-
tion, the cells were isolated and seeded in plastic petri
dishes at low density. Twenty-four hours after transfec-
tion, the resulting sodium current (INa) was recorded at
room temperature (23–25°C) under whole-cell voltage-
clamp conditions with an Axopatch 200B (Axon
Instruments, Inc., Jakarta Selatan, Indonesia) amplifier
interfaced to a personal computer driven by the PClamp
10 software (Molecular Devices Corporation, Sunnyvale,
CA). The leak and capacitive currents were canceled using
a P/4 protocol. The cells were bathed with an extracellular
solution containing (in mmol/L): NaCl 50, NMDG-Cl 80,
CsCl 5, MgCl2 1.2, CaCl2 2, HEPES 10, glucose 5. The
pH was adjusted to 7.4 with CsOH. Glass pipettes (tip
resistance: 1.3–2.5 MΩ) were filled with an intracellular
medium containing (in mmol/L): CsCl 60, aspartic acid
50, CaCl2 1, MgCl2 1, HEPES 10, EGTA 11, Na2ATP 5.
pH was adjusted to 7.2 with CsOH. All products were
purchased from Sigma.
Data analysis and statistical methods
Currents were analyzed with Clampfit software (Axon
Instruments, Inc). Data were analyzed using a combina-
tion of pClamp10, Excel (Microsoft, Redmond, WA) and
Prism (Graphpad, San Diego, CA).
Comparisons between groups were performed with two-
tailed Student’s t test or two-way ANOVA for normally
distributed parameters. Data are expressed as mean  SD.
A P-value <0.05 was considered statistically significant.
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Results
This study included 15 members of a large Iranian family
with BrS and a history of SCD (the pedigree is shown on
Fig. 1A, Tables 1 and 2).
The proband, a 48-year-old male, had been admitted to
a hospital because of recurrent syncopes related to night
eating and permanent dizziness. The first syncope had
occurred at 23 years of age. Two close relatives died sud-
denly at the ages of 36 (I.4) and 54 (II.5).
Brugada syndrome diagnosis was considered based on
spontaneous Brugada pattern on baseline ECG, with
ST-elevation in V1–V3 followed by negative T wave, and
maximal J-point elevation >7 mm in V2 (Fig. 1B). No
structural abnormality, valvular disease, or decreased con-
tractility was found by echocardiography. An ICD was
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Figure 1. (A) The pedigree, phenotypes, and mutation status of family members. Males and females are indicated by squares and circles,
respectively. The arrow shows the proband. SD: sudden death. ICD: implantable cardioverter defibrillator. (B) Representative 6-lead (V1–V6)
surface ECG of the proband showing a typical Brugada syndrome (BrS) pattern. (C) Representative 6-lead surface ECG of the III.9 individual
with a BrS type 2 pattern. (D) Chromatogram fragment of exon 26 of SCN5A gene. c.4516C>T heterozygote condition was shown by arrow
and change the Proline to Serine in codon 1506 of SCN5A gene. (E) Chromatogram fragment of KCNH2 gene. c.73C>T heterozygote condition
was shown by arrow and change the Arginine to Tryptophan in codon 25 of KCNH2 gene.
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implanted in 2012 and one appropriate shock was regis-
tered during the 1-year follow-up. No anti-arrhythmic
medication was administered. Genetic analysis of SCN5A
gene revealed a novel missense variant c.4516C>T leading
to the p.P1506S substitution (Fig. 1D). This variant was
not found in a control group of 100 ethnically matched
healthy volunteers (200 alleles). Clinical evaluations and
cascade genetic screening for the p.P1506S variant were
performed for an additional 13 relatives. BrS was sus-
pected in five family members (accordingly to a first
ECG). For three of them (II.3, III.1, and III.9), BrS diag-
nosis was made on the basis of a positive flecainide chal-
lenge test. Two patients with suspected diagnosis of BrS
(III.3 and III.4) declined pharmacological testing. An ICD
implantation was performed for the patient II.3. This
patient did not receive any anti-arrhythmic drugs and no
appropriate shock has been recorded during 1 year after
implantation.
Mutation screening in exon 26 of SCN5A revealed the
missense variant p.P1506S in five family members (II.3,
III.1, III.3, III.4, and III.6). Surprisingly, we did not find
the p.P1506S variant in one relative (III.9) with a clear
BrS pattern and presyncopal episodes in anamnesis
(Fig. 1C); his father (II.5) died suddenly at 54 years of
age during a third syncope.
Additional genetic screenings were performed for
KCNQ1, KCNE2, KCNE3, KCNE1, KCNJ2, KCNH2,
SCN5A, SCN1B, SCN3B, SCN4B, and SNTA1 genes for
SCN5A-negative BrS patient. The genetic variant c.73C>T
in KCNH2 gene isoform C (hERG-b), leading to the
p.R25W substitution, was found (Fig. 1F). Repeated cas-
cade family screening for this variant was carried out for
other family members, and it was detected in 7 of them
Table 1. Susceptibility genes for Brugada syndrome.
Gene
Type of
BrS
Detection
rate of
mutation (%)
The cardiac
voltage-gated
sodium channel and
associated proteins
SCN5A BrS 1 11–28
GPD1-L BrS 2 <1
SCN1B BrS 5 <1
SCN3B BrS 7 <1
MOG1 BrS 11 <1
SLMAP BrS 15 <1
SCN2B BrS 17 <1
Potassium channels and
associated proteins
KCNH2 BrS 8 <1
KCNE3 BrS 6 <1
KCNE5 BrS 12 <1
KCNJ8 BrS 9 <1
KCND3 BrS 13 <1
Calcium channel and
associated proteins
CACNA1c BrS 3 3–4
CACNB2b BrS 4 2–3
CACNA2D1 BrS 10 <1
Nonselective
cation channels
TRMP4 BrS 16 <6
Hyperpolarization
activated cyclic
nucleotide-gated
channels
HCN4 BrS 14 <1
BrS, Brugada syndrome.
Table 2. Clinical and genetic data of the family members.
Sex SCN5A p.P1506S KCNH2 p.R25W
Brugada pattern on 1st
ECG testing
Syncope HR PR msec QTc msec ICDSpontaneous After PCT
II.2 Proband M +/ / BrS 1 NP + 93 180–200 425 +
II.3 M +/ +/  + + 78 180–200 404 +
II.5 M / +/  Negative + NA NA NA No
II.6 F / /  NP  67 160–180 428 No
III.1 M +/ / BrS 1/BrS 2 +  78 200–220 413 R
III.2 M / /  NP  89 160 395 No
III.3 F +/ +/  Refused  NA 180–200 390 No
III.4 F +/ /  Refused  NA NA NA No
III.5 M / /  R  97 160–180 439 No
III.6 M +/ +/  R  65 160–180 428 No
III.7 F / +/  R  95 160–180 363 No
III.8 F / +/  R  73 140–160 404 No
III.9 M / +/  + + 81 140–160 380 R
III.10 M / /    100 180–200 405 No
BrS, Brugada syndrome; +/, present in heterozygous state; /, genetic variant is absent; NA, not available; NP, not performed; R, recom-
mended; Refused, test was recommended but refused.
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(II.3, II.5, III.3, III.6, III.7, III.8, and III.9). Clinical and
genetic findings from the family members are summa-
rized in the Table 1.
To investigate the functional consequences of the
p.P1505S mutation on Na+ channel activity, we used the
whole-cell configuration of the patch-clamp technique.
The presence of the mutation reduced the peak current
density of Nav1.5 (current density at -20 mV (pA/pF):
119  21, n = 6, versus 58  16, n = 8, **P < 0.01;
for WT and mutant channels, respectively, Fig. 2A and
B). The voltage dependence of steady state of activation
was shifted toward more positive potentials (V1/2 act:
24  2 mV, n = 6, vs. 15  2.8 mV, n = 8, *P <
0.05; slope: 6  0.3 mV vs. 8.8  0.6 mV, **P < 0.01;
for WT and mutant channels, respectively, Fig. 2C). In
addition, the voltage dependence of steady state inactiva-
tion was shifted toward more negative potentials in the
presence of the p.P1505S mutation (V1/2 act: 66  2
mV, n = 6, vs. 80  4 mV, n = 8, **P < 0.01; slope:
6.1  0.5 mV vs. 5.6  0.2 mV; for WT and mutant
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Figure 2. (A) Current traces obtained with inset protocol from Nav1.5-WT and Nav1.5-P1505S transfected HEK293 cells. (B) Current-voltage
traces of the Nav1.5-WT and Nav1.5-P1505S channels. (C) Steady-state activation and inactivation curves. Activation properties were
determined from I/V relationships by normalizing peak INa to driving force and maximal INa. Parameters for the voltage-dependence steady state
of activation and steady state of inactivation (20-msec test pulse to -10 mV after a 500 msec conditioning prepulse). (D) Sodium current time-
to-peak values were used to evaluate the activation kinetics. (E) Fast inactivation time constants were measured by fitting the inactivation phase
of the Na+ current to a single exponential equation for WT and p.I141V. For D and E, to avoid being biased by the positive shift of the voltage
dependence of activation, for each individual cell, the first analyzed potential (sweep 1) was corresponding to the potential for which the
amount of the activated channels is more than 20%. For the statistical analysis, a two-way ANOVA test followed by a Bonferroni correction
was used to compare point by point the measured activation and inactivation ***, P < 0.001, **<0.01 versus WT. (F) Recovery from fast
inactivation was measured using a twin-pulse protocol (in inset).
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channels, respectively, Fig. 2C). For a given command
voltage, the activation and inactivation kinetics were has-
tened in the mutant channel (Fig. 2D and E) However,
no significant differences were observed regarding the
recovery from fast inactivation (t1/2 of recovery from
inactivation: 9.4  1.3 msec, n = 4, versus 9.3  1 msec,
n = 7; Fig. 2F).
Discussion
This study reports on a large Iranian family with BrS
where the proband and several of its relatives carry a
novel missense mutation p.P1506S in the SCN5A gene.
PQ interval prolongation >200 msec in patients with
Brugada syndrome caused by SCN5A mutations has been
described previously (Smits et al. 2002). The PQ interval
duration in SCN5A-positive family members was signifi-
cantly longer than in noncarriers (Table 3), and we con-
sider this fact as an indirect evidence of the association of
the p.P1506S variant with a clinical phenotype. In the
presence of this mutation, the electrophysiological study
revealed a significant loss of function of sodium current
related to a destabilization of the open conformation of
the Nav1.5 channel. This effect is reflected by a positive
shift of steady state of activation, a negative shift of steady
state of inactivation, and an acceleration of the inactiva-
tion kinetics. Reduction in sodium current is typical for
known SCN5A mutations leading to BrS, and we suggest
that the new missense mutation p.P1506S is linked with
the described BrS in this family.
However, one affected family member did not carry
this mutation and this discrepancy in segregation needs
additional explanation. Similar clinical observations
of three independent families with genotype-negative
phenotype-positive patients was previously reported by
Probst et al. (2009) suggesting that, in some cases, loss-
of-function SCN5A-mutation might not be sufficient to
cause BrS but could act as a predisposing or a modu-
lating factor. This suggestion was supported by the
recent study by Bezzina et al. (2013) showing that com-
mon genetic variants can have a strong impact on the
manifestation of BrS.
The coexistence of two independent mutations in the
same family is common in cardiac channelopathies
patients. The prevalence of compound heterozygosity has
been reported to amount from 4% to 7.9% in several
cohorts of LQTS patients, and the carriage of three inde-
pendent mutations was found in about 1% of genotype-
positive patients (Zaklyazminskaya and Abriel 2012).
The spectrum of genes causing LQTS and BrS is similar
and a similar prevalence of two independent mutations in
BrS cohorts may also be expected. In the current pedi-
gree, we propose that SCN5A-negative affected family
member may have BrS caused by mutations in another
gene.
We have used semiconductor sequencing PGM Ion
Torrent platform to resequence the SCN5A gene and
sequenced 10 additional susceptibility genes for BrS. A
missense mutation p.R25W in KCNH2 has been found in
SCN5A-negative BrS patient.
The KCNH2 gene encoded the alpha-subunit of the
rapid delayed rectifier K+ channel (IKr). Most of known
mutations in KCNH2 gene were associated with LQTS and
SQTS, and only a few variants were found in BrS patients
(Verkerk et al. 2005; Itoh et al. 2009; Nielsen et al. 2013;
Wang et al. 2014). The hERG1b-p.R25W variant has been
shown to induce a loss of function of hERG channel and
was associated with intrauterine unexplained fetal death
(Crotti et al. 2013). Nevertheless, taking into account the
hypothesis that p.R25W presented in hERG-b isoform
might affect the QT interval duration, we compared the
corrected QT interval values in KCNH2-positive and
KCNH2-negative family members (Table 3). The duration
of QTc in patients carrying only the KCNH2-p.R25W var-
iant was significantly shorter than in those who carried
only the SCN5A mutation (P < 0.05) (Table 4). Recently,
it was shown that QTc duration in KCNH2-related
patients tends to be shorter comparing with QTc in
SCN5A-related Japanese BrS patients (Ohno et al. 2011).
There was no significant difference in QTc duration
between patients with one genetic variant versus double
mutation carriers in our study.
It may be proposed that the p.R25W variant in the
KCNH2 gene might be a causative variant in the SCN5A-
negative BrS family member.
Table 3. Evaluation of PR interval durations in SCN5A-positive
versus SCN5A-negative family members.
Genetic variant Number of carriers PR msec P-value
SCN5A p.P1506S/N 6 190  14.1 0.01
SCN5A N/N 4 156  11.5
Table 4. Evaluation of QTc interval durations in patients with
combinations of KCNH2 and SCN5A variants.
Genetic variants combination
Number
of carriers QTc msec
SCN5A p.P1506S/N and KCNH2 N/N 3 419  8.4
SCN5A p.P1506S/N and KCNH2 R25W/N 3 407  19.2
SCN5A N/N and KCNH2 p.R25W/N 4 382  20.5
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Conclusion
Here, we presented a large family where two independent
rare genetic variants were identified in patients with BrS.
A new missense mutation p.P1506S in the SCN5A gene
leads to a significant reduction in Na+ current related to
a destabilization of the open conformation of Nav1.5. We
propose that the p.P1506S mutation in SCN5A is causa-
tive for BrS in most of the affected family members. Rare
genetic variant p.R25W in KCNH2 gene might be respon-
sible for BrS phenotype in SCN5A-negative affected family
members. The precise molecular mechanism leading to
BrS for this variant remains to be elucidated. Further
genetic and functional studies analyzing genotype–pheno-
type correlations in BrS are required. We illustrate that
the concept by default “one family-one phenotype-one
causative genetic variant” is not always applicable for
families with cardiac channelopathies, and comprehensive
genetic testing can be important for family screening and
genetic counseling.
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